Today: 30 June 2026
Singapore Airlines stock slips from 2-day run as investors turn cautious; Feb 24 update in focus
6 February 2026
1 min read

Singapore Airlines stock slips from 2-day run as investors turn cautious; Feb 24 update in focus

Singapore, Feb 6, 2026, 15:35 SGT — Regular session.

  • Singapore Airlines shares slipped 0.45% to S$6.68, following gains of roughly 1.9% and 1.7% over the previous two days
  • Traders juggle Airshow deal news amid a weaker mood in Asian equities
  • The next major event: the carrier’s third-quarter business update, scheduled after the close on Feb 24

Shares of Singapore Airlines Ltd slipped 0.45% to S$6.68 by mid-afternoon Friday in Singapore, retreating after two days of gains. The stock fluctuated between S$6.62 and S$6.70, with roughly 4.9 million shares traded.

The pullback coincided with a broader shift toward defensiveness in Asian markets, as investors pared back risk following a tech-driven stumble. “What we’re seeing now feels more like investors de-risking and locking in gains,” said Zavier Wong, a market analyst at eToro. https://www.reuters.com/world/china/tech-l…

Airlines grabbed attention at the Singapore Airshow this week as manufacturers and suppliers pitched solutions to the industry’s maintenance bottleneck. Boeing announced its largest landing gear exchange deal yet, struck with the Singapore Airlines Group. The contract covers more than 75 aircraft across the group’s 737 MAX and 787 fleets, aiming to swap in overhauled gear and cut downtime. “By combining our global inventory and rapid distribution capabilities with the carrier’s maintenance planning, this agreement helps deliver parts faster and closer to operations—reducing downtime and supporting consistent, reliable service,” said Boeing Global Services executive William Ampofo. https://boeing.mediaroom.com/news-releases…

Cost remains the bigger headache. Supply bottlenecks have settled into a “new norm,” said ST Engineering’s commercial aerospace COO Jeffrey Lam in an interview with Reuters. Scoot CEO Leslie Thng added the budget carrier has had to “secure more spare engines at our own expense” to buffer against disruptions. IATA Director General Willie Walsh pegged the extra cost from airlines running older planes longer at around $11 billion in 2025, labeling the situation “very frustrating.” https://www.reuters.com/business/aerospace…

Singapore Airlines investors face these pressures as the company prepares to report its FY2025/26 third-quarter update. The airline plans to release the numbers Tuesday, Feb. 24, after the market closes.

The update is set to shed new light on passenger yields, capacity, and cargo trends, as well as whether rising maintenance and leasing expenses are squeezing margins. Insights on aircraft availability will also be crucial, with airlines balancing delayed deliveries against limited access to spare parts.

Downside risks are clear. A sudden spike in jet fuel prices would hit the sector fast. Meanwhile, ongoing parts shortages might force airlines to run less fuel-efficient planes longer, pushing unit costs up even if demand stays steady.

Traders are closely eyeing if Singapore Airlines can sustain this week’s gains through the close. Attention also turns to the Airshow for any updates on maintenance capacity and delivery schedules that might shift outlooks before the Feb. 24 update.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Theravance Biopharma (TBPH) Slides 3% After $929M Zymeworks (ZYME) Deal Announced
    June 30, 2026, 10:24 AM EDT. Theravance Biopharma (TBPH) shares slipped about 3% on June 29, 2026, after Zymeworks (ZYME) said it would buy the company in an all-cash deal valued at around $929 million. The deal is set to close in H2 2026. Theravance went up for sale after its main drug, ampreloxetine, missed in Phase III trials. Most of Theravance's revenue came from a single COPD collaboration. The buyout gives shareholders $17 per share, which is a 22% premium to the March 3 close, plus CVRs linked to future ampreloxetine proceeds. Management called the move the best route for shareholder value as operational cuts and slow growth continue. Theravance has a Zacks Rank #4 (Sell).
NIO stock jumps after profit alert flags first quarterly operating profit — what investors watch next
Previous Story

NIO stock jumps after profit alert flags first quarterly operating profit — what investors watch next

Ford stock slips before market open as EV sales dive and Geely talks linger
Next Story

Ford stock slips before market open as EV sales dive and Geely talks linger

Go toTop